NasdaqGM:SPRYBiotechs
Assessing ARS Pharmaceuticals (SPRY) Valuation After China Community Approval For Neffy Epinephrine Spray
China approval puts focus on ARS Pharmaceuticals’ new market opportunity
ARS Pharmaceuticals (SPRY) is back on investor radar after partner Pediatrix Therapeutics received approval from China’s National Medical Products Association for community use of neffy, its intranasal epinephrine spray.
This decision makes neffy the first government approved epinephrine product for use outside Chinese hospitals. It creates a fresh addressable market and sets up ARS to collect regulatory milestone...